🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase III Pipeline Programs

Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Programs
5,427

Quick answer

NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Top sponsors

Page 39 of 114

  1. Glecaprevir/Pibrentasvir

    AbbVie

    Hepatitis C Virus (HCV)

    phase 3 small molecule completed

    2 trials

  2. Glepaglutide 20.0 mg/mL

    Zealand Pharma A/S

    Short bowel syndrome

    phase 3 small molecule active

    1 trial

  3. Glepaglutide 20.0 mg/mL

    Zealand Pharma A/S

    Short Bowel Syndrome

    phase 3 small molecule active

    1 trial

  4. Glepaglutide 20.0 mg/mL, Glepaglutide Placebo

    Zealand Pharma A/S

    Short Bowel Syndrome

    phase 3 small molecule active

    1 trial

  5. Glimepiride

    Janssen Cilag International NV

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  6. Glipizide

    GlaxoSmithKline

    Atherosclerosis

    phase 3 small molecule completed

    1 trial

  7. Glucagon

    Xeris Biopharma Holdings

    Diabetes Mellitus, Type 1

    phase 3 small molecule completed

    1 trial

  8. Glucose 5% 50 ml

    Disc Medicine

    Apnea of prematurity

    phase 3 small molecule active

    1 trial

  9. Glycerin Suppository

    United Therapeutics Europe Ltd

    Encopresis

    phase 3 small molecule completed

    1 trial

  10. Glycopyrronium bromide

    Novartis Pharmaceuticals

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule completed

    1 trial

  11. Golimumab 1 mg per kg

    Janssen Cilag International NV

    Colitis, Ulcerative

    phase 3 small molecule terminated

    1 trial

  12. Gonal-F

    The First People's Hospital of Lianyungang

    Anovulation

    phase 3 mab completed

    1 trial

  13. Grafalon 20 mg/ml concentrato per soluzione per infusione

    The George Institute

    To analyze whether the anti-rejection treatment of borderline lesions can modify the expression and klotho levels, as well as proinflammatory cytokines that regulate klotho expression at both years post-transplant., Know in a controlled and randomized clinical trial, carried out in low-risk patients immunological and stable renal function, if the treatment of BL lesions, detected in the third month post-transplant, with rabbit polyclonal antilymphocytic globulin prevents or slows the progression of chronic histological lesions of the graft (FIAT) and the deterioration of its function compared to clinical follow-up conventional, after two years of post-transplant follow-up.

    phase 3 small molecule active

    1 trial

  14. Granules for oral suspension, N-Acetyl-L-Leucine

    Intrabio Ireland Limited

    Niemann-Pick disease type C

    phase 3 small molecule active

    1 trial

  15. Granulocyte Colony-Stimulating Factor(G-CSF)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Myelodysplastic Syndrome

    phase 3 small molecule active

    2 trials

  16. Gum chewing

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co.,

    Recovery of Bowel Function, Due to Gum Chewing

    phase 3 other active

    1 trial

  17. Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab, Guselkumab

    Janssen-Cilag International N.V.

    Juvenile psoriatic arthritis (jPsA), Moderately to severely active ulcerative colitis (UC), Moderately to severely active Crohn's disease (CD)

    phase 3 small molecule active

    1 trial

  18. Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab, Guselkumab- Solution for infusion- 10 mg/ml

    Janssen-Cilag International N.V.

    Crohn’s Disease

    phase 3 small molecule active

    1 trial

  19. Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab, STELARA 90 mg solution for injection in pre-filled syringe, Placebo for Ustekimumab, Placebo for Guselkumab, STELARA 130 mg concentrate for solution for infusion

    Janssen-Cilag International N.V.

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

  20. Guselkumab 1 mL PFS Placebo, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL

    Janssen-Cilag International N.V.

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  21. Guselkumab 1 mL PFS Placebo, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL

    Janssen-Cilag International N.V.

    Moderate to Severe Plaque Type Psoriasis

    phase 3 small molecule active

    1 trial

  22. Guselkumab 1 mL PFS Placebo, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL

    Janssen-Cilag International N.V.

    Moderately to Severely Active Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  23. Guselkumab 1 mL PFS Placebo, Guselkumab, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab 2 mL PFS Placebo, Guselkumab 0.5 mL Varioject Placebo, Guselkumab, Guselkumab- Solution for infusion- 10 mg/ml

    Janssen-Cilag International N.V.

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  24. Guselkumab Dose 1

    Janssen Cilag International NV

    Crohn's Disease

    phase 3 small molecule active

    1 trial

  25. Guselkumab, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab 1 mL PFS Placebo, Guselkumab 2 mL PFS Placebo

    Janssen-Cilag International N.V.

    Moderate to Severly Active Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  26. Guselkumab, Placebo 0.5ml equivalent, Guselkumab- Solution for infusion- 10 mg/ml, Placebo 2.0ml equivalent, Guselkumab, Placebo 1.0ml equivalent, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL

    Janssen-Cilag International N.V.

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

  27. Guselkumab- Solution for infusion- 10 mg/ml, Placebo to Guselkumab, Placebo to Guselkumab solution for injection in pre-filled syringe -100 mg/ml, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab, Placebo to Guselkumab- Solution for infusion- 10 mg/ml

    Janssen-Cilag International N.V.

    Fistulizing perianal Crohn's Disease

    phase 3 small molecule active

    1 trial

  28. Gynaecological follow-up

    GlaxoSmithKline

    Infections, Papillomavirus

    phase 3 other completed

    1 trial

  29. H. pylori vaccine

    BRIGHT MINDS BIOSCIENCES INC.

    H. Pylori Infection

    phase 3 mab completed

    1 trial

  30. H. pylori vaccine

    Jiangsu Province Centers for Disease Control and Prevention

    H. Pylori Infection

    phase 3 mab completed

    1 trial

  31. H006629, H006629, H006629, LEVODOPA AND DECARBOXYLASE INHIBITOR , H006629

    Zambon SpA

    Motor fluctuations in advanced Parkinson’s disease

    phase 3 small molecule active

    1 trial

  32. H5N1 adjuvanted split virus vaccine (A/Vietnam/1194/2004 strain)

    GlaxoSmithKline

    Influenza

    phase 3 mab completed

    1 trial

  33. HBS-101, White, round, plain, biconvex film-coated tablet. Matching 4.45 mg tablet is 3.7 mm in diameter., White, round, plain, biconvex film-coated tablet. matching 17.8 mg tablet is 7.5 mm in diameter., WAKIX, HBS-101, WAKIX

    Harmony Biosciences Holdings

    Prader-Willi syndrome

    phase 3 small molecule active

    1 trial

  34. HBS-301 tablet

    Harmony Biosciences Holdings

    Idiopathic Hypersomnia

    phase 3 small molecule active

    1 trial

  35. HD201

    Prestige Biopharma Belgium

    HER2 Positive Breast Cancer

    phase 3 small molecule completed

    1 trial

  36. HEC585

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Idiopathic Pulmonary Fibrosis (IPF)

    phase 3 small molecule active

    1 trial

  37. HEC74647PA+HEC110114

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Chronic HCV Infection

    phase 3 small molecule completed

    1 trial

  38. HEPARIN , NADROPARIN

    Disc Medicine

    All patients who receive ECMO treatment during the study period in one the participating centers from which (deferred) informed consent is obtained. Patients in whom the ECMO is only used to bridge a procedure like a high risk percutaneous coronary intervention or during surgery are excluded.

    phase 3 small molecule active

    1 trial

  39. HETLIOZ 20 mg hard capsules, Placebo will be provided in size and appearance identical to those containing tasimelteon and will be administered orally.

    Lacuna Pharma Pty Ltd

    Delayed Sleep-Wake Phase Disorder (DSWPD)

    phase 3 small molecule active

    1 trial

  40. HIPEC with neoadjuvant chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric Cancer

    phase 3 other active

    1 trial

  41. HLD200 methylphenidate hydrochloride capsules

    COLLEGIUM PHARMACEUTICAL, INC

    Attention Deficit Hyperactivity Disorder

    phase 3 small molecule terminated

    1 trial

  42. HLX02

    Shanghai Henlius Biotech

    Breast Cancer

    phase 3 mab completed

    1 trial

  43. HOLOXAN 2000 mg, poudre pour usage parentéral, DETICENE 100 mg, poudre et solvant pour solution pour perfusion, DOXORUBICINE ACCORD 2 mg/ml, solution pour perfusion

    The George Institute

    Resectable, non-metastatic soft-tissue sarcoma (STS)

    phase 3 small molecule active

    1 trial

  44. HS-20094 Injection

    Jian Li

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  45. HUMAN NORMAL IMMUNOGLOBULIN (IV), Placebo for empasiprubart- solution for IV infusion, Placebo for IVIg - solution for IV infusion, ARGX-117

    argenx

    Chronic inflammatory demyelinating polyneuropathy (CIDP)

    phase 3 small molecule active

    1 trial

  46. HVA

    The First People's Hospital of Lianyungang

    Newly Diagnosed Acute Myeloid Leukemia With High Risk

    phase 3 small molecule active

    1 trial

  47. HYCAMTIN 4 mg powder for concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion

    Gilead Sciences Pty Limited

    Extensive Stage Small Cell Lung Cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial

  48. HYDROCORTISONE, PREDNISONE ACETATE, ENZALUTAMIDE, DEXAMETHASONE ACETATE, PREDNISONE, Opevesostat, ABIRATERONE ACETATE, DEXAMETHASONE, HYDROCORTISONE , HYDROCORTISONE, FLUDROCORTISONE, ABIRATERONE ACETATE, PREDNISOLONE, HYDROCORTISONE, FLUDROCORTISONE ACETATE

    Merck Sharp and Dohme

    Metastatic castration resistant prostate cancer

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many Phase III pipeline programs are in the directory?

5,427 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.